CO-DIAGNOSTICS DL-,001 Forum: Community User: tms33

Hi Torofeo: 17.06.21 War die Präsentation von Eikon-Plattform, mehr ist mir nicht bekannt. Hast du was von Q2 gehört?

Hier im Forum ist echt nur noch der hatte Kern unterwegs. Gibt es schon eine Info wann man mit der Zulassung von eikon rechnen kann? Beantragt ist sie doch oder?

Sehe es genauso. Auch wenn die erst in 1-2 Jahren fliegt, habt ihr immer noch mehr Rendite als bei der Bank. Daher alles gut

Moritz, weil bei dem geringen Volumen es ein leichtes Spiel ist das Ding zu drücken. Lass liegen, es wird wieder steigen. Cash im Wert von ca 3 USD/Aktie sprechen für sich. Ich verstehe das mangelnde Interesse an der Aktie auch nicht. Ich sehe in dem Unternehmen viel Potential. Deswegen lasse ich meine Aktien liegen Und freue mich in ein paar Jahren.

Kann es sein das Ende q2 ist und einige aussteigen um Verluste zu realisieren? Sind ende Q2 short Positionen zu covern?

sorry für doppelt!

Wei0 jemand warum sie in Minus heute ist? Keine Ahnung - vielen Dank!

Kann jemand dieses Minus erklären - keine Ahnung dazu, vielen Dank!

Nur 230 000 Aktien an der NASDAQ gehandelt. Das ist zu wenig. Aber immerhin grün.

Vllt diesmal was nachhaltiges

Physio es scheint ein Impuls da zu sein 🤗

Jetzt braucht es aber deutliche Impulse um den Kurs über die 10 USD zu bringen. Wenn zeitnahe keine guten News kommen wird sie ewig dahin dümpeln.....gähn.....

Hallo alle zusammen...die letzten Tage hält CODX sich gut🙌das lässt hoffen Durch die Delta Variante wird wieder Schwung in die Covidaktien kommen wobei CODX für mich persönlich weit aus mehr ist als nur Covid

DACHTE der Link geht für alle

Danke Sgarleos und MarkusWW

SALT LAKE CITY, June 18, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smartâ„¢ SARS-CoV-2 DS (Direct Saliva) has obtained regulatory authorization to be sold as an in vitro diagnostic ("IVD") for the diagnosis of COVID-19 in markets that accept CE markings, and is now available for purchase from the Company's Utah-based ISO-13485:2016 certified facility. Co-Diagnostics' Logix Smart DS test kit is designed to detect the presence of the RdRp and E genes of SARS-CoV-2 directly from minimally processed human saliva samples while eliminating RNA extraction of the samples, a costly and time-consuming process required by most PCR tests. Co-Diagnostics believes that eliminating the extraction process has the potential to increase throughput and lower costs of not only COVID-19 testing, but also any other pathogen for which the Company develops a direct saliva test. Dwight Egan, Chief Executive Officer of Co-Diagnostics, commented, "We are pleased to announce that this new, simplified PCR testing method is now available as an IVD in any country that accepts a CE marking as valid regulatory approval to aid in the ongoing battle against the COVID-19 pandemic, which we anticipate will drive demand for diagnostics as normalization testing protocols are established. We believe that the need for testing will especially persist in countries where vaccination rates lag substantially behind those of the United States. "The direct saliva technical advance represents one of the important innovations that the Company has developed since the pandemic began. Our unique CoPrimerâ„¢ technology utilized in this test design received initial patent protection in 2018, which was further strengthened by an additional patent last year. In combination with this technology, direct saliva testing will play a key role in our ongoing centralized lab initiative, as well as our forthcoming at home and point of care testing strategies. As a Company, we are particularly pleased with the dedication and hard work performed by our scientific, laboratory and regulatory staff that has culminated in this significant achievement. "The quality of our tests and technology have been consistently borne out both here in the United States and in over 50 countries internationally as Co-Diagnostics has been chosen by prestigious laboratories who specialize in providing highly accurate PCR testing. We believe this CE marking is a critical indicator of our goal to bring high quality, affordable molecular diagnostics to nations across the world, where our distributors and customers have come to depend on the quality, accuracy, and affordability of our diagnostic products, and of our commitment since the earliest days of the pandemic to remain on the forefront of the fight against COVID-19." The CE Marking for the Logix Smart DS CE-IVD Test confirms that it meets the Essential Requirements of the European Community's In-Vitro Diagnostic Medical Device Directive (IVDD 98/79/EC), permitting export and sales of the product as an IVD to commence immediately in the European Community. Many other global markets also accept a CE marking as valid regulatory approval following routine local product registration, which allows sales of the Company's IVD into these areas as well. About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures, and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.